导管切除与抗心律失常药物治疗心室高心率:系统性审查和元分析
Sufyan Shahid1, Shehroze Tabassum2, Muhammad Abdullah Ali3
1Khawaja Muhammad Safdar Medical College, Sialkot, Pakistan.
Critical pathways in cardiology
|November 4, 2025
概括
导管切除和抗心律失常药物显示出类似的有效性和安全性,用于管理心室动脉冲动. 需要进一步的研究来证实这些发现的VT管理.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 医学研究 医学研究
背景情况:
- 突然心脏病死亡 (SCD) 由于心室高心率 (VT) 和动导致显著的死亡率.
- 导管切除 (CA) 和抗失律药物 (AAD) 是复发性静脉瘤的主要治疗方法,但它们的相对有效性尚不清楚.
研究的目的:
- 系统地审查和元分析随机对照试验 (RCT),比较患有缺血性心肌病的患者的CA和AAD,以及植入式心脏转换器-除器 (ICD).
主要方法:
- 在PubMed,Embase和Cochrane中央图书馆进行了系统的文献搜索,截至2025年2月15日.
- 三个涉及587名患者的RCT (287名CA,300名AAD) 被纳入了分析.
- 随机效应模型被用于组合风险比率 (RRs) 和95%置信区间 (CI) 的主要和次要结果.
主要成果:
- 对于全因死亡率,心血管死亡率,静脉风暴或适当的ICD冲击,没有观察到CA和AAD之间的显著差异.
- 二次结果,包括不适当的ICD冲击,抗心动节奏,心力衰竭住院,中风/TIA和心肌梗塞,也在两组之间相似.
结论:
- 导管切除和抗心律失常药物在患有心室性心跳动的患者中表现出可比的疗效和安全性.
- 需要进行更大规模,高质量的试验来验证这些结果,并探索CA作为静脉瘤一线治疗的潜力.
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K
Dysrhythmias VI: Management of Dysrhythmias
424
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
424
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
446
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
446
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.7K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.9K


